| Keywords: |
treatment response; doxorubicin; note; letter; neoplasm; ovarian neoplasms; quality of life; ovary cancer; neoplasm recurrence, local; peritoneal neoplasms; tumor recurrence; ovary tumor; drug derivative; fallopian tube neoplasms; peritoneum tumor; polyethylene glycols; epothilones; epothilone b; epothilone derivative; neoplasms, glandular and epithelial; uterine tube tumor; phase 3 clinical trial (topic); macrogol derivative; humans; human; female; priority journal; platinum resistant ovarian cancer
|
